ZYDUSLIFE Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹8,017 Cr
verified against source
Revenue YoY
22%
reported change
EBITDA
₹1,930 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Zydus Lifesciences delivered a strong Q1 FY27 with 22% YoY revenue growth to ₹8,022 crore, driven by broad-based outperformance across India formulations (+20%), international markets (+34%), and consumer wellness (+67%). EBITDA margin of 24.1% reflects robust profitability despite incremental investments in specialty pipeline. The US specialty business now contributes 10% of revenue and is on track to exceed 15% by year-end. Key catalysts ahead include Saroglitazar's US launch (FY28), the Associo acquisition contributing $15-20M quarterly run-rate, and biosimilar scale-up. Management guides to 24%+ EBITDA margins for FY27 despite SRO investments, while targeting 28-30% margins over a 5-year horizon as branded revenue mix shifts beyond two-thirds. Key risks include SRO launch costs weighing on near-term margins, currency headwinds in North America, and competitive pressure in the US generics segment.
Colored figures show movement against the previous available record.
Guidance to track
- India formulations expected to deliver mid-teens growth (300-500bps above market); international markets to sustain strong performance; US generics ~single-digit growth.
- Despite meaningful incremental SRO investments in second half, management maintains 24%+ EBITDA margin guidance. Current quarterly run-rate (ex-R&D) is ₹1,900-2,000 crore.
- Investments include SEZ3 facility, formulation R&D center, biologics/vaccines DS facility, consumer wellness land acquisition, and ongoing Zydus injectable capacity expansion.
- Branded portfolio currently >55% of revenue; management targets >66% share as India branded, US specialty, and innovation businesses scale. Margins expected to improve to 28-30% range over 5-year horizon.
Risks flagged
- First two years post-April 2028 SRO launch will be primarily investment/buildout phase with minimal revenue contribution. Management acknowledged significant cost increases in second half of FY27.
- MiraBon settlement-related royalty costs impacted Q1 gross margins QoQ; amortization from licensing arrangement continues through Q2 FY28. Analyst Surya asked about sustainability of margin recovery.
- Niha raised concerns about sharp QoQ increase in other expenses (~80% driven by acquisitions). Management attributed current run-rate to ongoing Associo integration costs.
- China market entry for Saroglitazar requires NRDL reimbursement listing; management declined to quantify steady-state sales potential, citing 2-3 quarters before providing clarity on access timeline.
Key quotes
- We are willing for a next FY28 launch. The first two years will be just a buildup of this. So we won't see any significant revenue in the first year, but as we move into second and third year we would see the revenue build up.
- On our conservative side we're looking at a 200 to 300 million range and we may be more optimistic we can cross the 400 plus million range.
- If we are able to scale up a branded business towards the 2/3 then we should see an improvement in our margins. Ideally we would want to be improving our EBITDA margins to the 28-30% range as we move closer to the 5-year period long.
Research modules